In summary, this 13-year longitudinal follow-up of men with severe hemophilia B confirms the long-term safety of AAV gene therapy associated with durable factor IX expression, accompanied by lasting improvement in hemostasis and reduction in the need for factor IX prophylaxis. Here, F9 is linked to hemophilia B.